SC
RYTM icon

Scholtz & Company’s Rhythm Pharmaceuticals RYTM Stock Holding History

Scholtz & Company’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-9,413
Closed -$280K – 80
2020
Q4 		$280K Buy
+9,413
New +$239K 0.11% 68

Other funds holding RYTM

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Scholtz & Company's RYTM Position: Q1 2021 in Review

Scholtz & Company sold out of Rhythm Pharmaceuticals (RYTM) in Q1 2021, closing a stake of 9,413 shares — an estimated $280K sold.

Scholtz & Company first reported a position in RYTM in Q4 2020 and held it in 1 quarter. The position peaked at $280K in Q4 2020. 124 funds tracked by Wall St. Rank hold RYTM as of Q1 2021.

  • Scholtz & Company reported no remaining Rhythm Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Scholtz & Company sold 9,413 Rhythm Pharmaceuticals shares in Q1 2021, an estimated $280K.
  • Scholtz & Company first reported a position in Rhythm Pharmaceuticals in Q4 2020 and held it in 1 quarter.
  • Scholtz & Company's Rhythm Pharmaceuticals position peaked at $280K in Q4 2020.
  • 124 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2021.

Based on Scholtz & Company's 13F filing for Q1 2021, filed 17 May 2021.